This systematic review aims to investigate how the presence of NRAS, KRAS, or BRAF mutation in non-metastatic MSI colon cancer patients affects outcomes such as DFS, OS, and survival after recurrence (SAR). The gene discussed is BRAF; the disease is malignant colon neoplasm.